February 6, 2012—In apparent response to urgent appeals by safety-net providers, drug manufacturer Sanofi U.S. has announced that it is reinstating patient assistance for its anti-coagulant Lovenox effective Feb. 15.
The company discontinued its patient assistance program (PAP) for the widely used drug in late December. It also ended its entire institutional patient assistance program (IPAP) at the same time.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)